<DOC>
	<DOCNO>NCT00645073</DOCNO>
	<brief_summary>To compare safety efficacy ten-day course therapy cefdinir , 600 mg QD , ten-day course therapy levofloxacin , 500 mg QD , treatment acute bacterial sinusitis .</brief_summary>
	<brief_title>Study Safety Efficacy Cefdinir Levofloxacin Treatment Subjects With Acute Bacterial Sinusitis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Cefdinir</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>A female must nonlactating , nonbreastfeeding risk pregnancy . A condition general good health , base upon result medical history , physical examination , laboratory profile . Subject must diagnosis acute bacterial sinusitis . The diagnosis must base following : sinus radiograph CT scan perform within 48 hour pretreatment evidence maxillary opacification air/fluid level Purulent discharge nose At least one follow clinical sign symptom acute bacterial sinusitis Lasting 7 day prior longer 21 day Evaluation 1 : facial pain sinus facial pressure sinus facial tightness sinus facial swell toothache . Subject must suitable candidate oral antimicrobial therapy able swallow capsule intact . Subjects : chronic sinusitis ( sign symptom last great 28 day prior Evaluation 1 ) Significant anatomical abnormality sinuses Any infection condition necessitates use concomitant systemic antimicrobial . History hypersensitivity allergic reaction penicillin , cephalosporin ( include cefdinir ) , quinolones ( include levofloxacin ) . Subject take : systemic antibiotic within 14 day study drug administration ; long act injectable antibiotic ( e.g. , penicillin G benzathine ) within 30 day study drug administration . Known significant renal hepatic impairment . Evidence uncontrolled clinically significant cardiovascular , pulmonary , metabolic , gastrointestinal , neurological endocrine disease , malignancy , abnormality ( disease study ) . Investigator considers subject unsuitable cefdinir levofloxacin therapy , reason . Previous enrollment study . Any underlying condition disease state would interfere completion study procedure evaluation absorption study drug . Subject currently receive likely require follow medication period Evaluation 1 ( initial presentation office/clinic ) Evaluation 3 ( within 48 hour last dose study drug ) : Concomitant theophylline theophylline analog , unless plasma level drug adequately monitor study ; Warfarin probenecid . Immunocompromised subject . Subject require parenteral antibiotic therapy infection infection condition , necessitates use concomitant systemic antibiotic . Subjects receive antacid contain magnesium , aluminum , well sucralfate , metal cation iron , multivitamin preparation zinc within 2 hour dose study drug . Subjects know suspected central nervous system disorder may predispose subject seizure low seizure threshold .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Acute Bacterial Sinusitis</keyword>
</DOC>